Medical Licensing (MD/DO) · Independent exam preparation
ABU Qualifying (Part 1) Examination: Free Preparation Guide Study Guide
Practise urgent drainage, cancer treatment, obstruction testing and fertility-safe treatment through 60 focused concepts and 20 ABU Part 1 learning questions.
By CertMedbry · Updated 18 October 2026
Decide when to drain an infected collecting system, repeat cancer staging, distinguish obstruction from weak detrusor contraction, and protect fertility or renal function. This guide connects mechanisms with clinical decisions across all eight study domains for the American Board of Urology Qualifying (Part 1) Examination. Its 60 concepts provide selective preparation; the official ABU content outline defines the full examination scope.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and certification pathway does this guide cover?
The official examination is the Qualifying (Part 1) Examination issued by The American Board of Urology, Inc. This guide follows the initial certification pathway for eligible urologists trained in approved U.S. or Canadian programs. Part 1 assesses knowledge; completing it alone does not confer board certification. The subsequent Certifying (Part 2) Examination includes practice assessment and oral examinations, including OSCE components. Those Part 2 formats do not describe Part 1.
ABU: 2027 Information for Applicants and Candidates · ABU: Qualifying Examination (Part 1)
How do Canadian training and the alternate pathway affect examination identity?
The handbook recognizes specified U.S. and Canadian training routes. Canadian-trained candidates do not need RCPS(C) certification for admission to Part 1, but require it for admission to Part 2. An individually reviewed alternate pathway also exists for certain internationally trained academic urologists. These are eligibility routes into the ABU certification process, rather than separate Part 1 examinations or Canadian certification examinations.
How many questions are scored, and how long is the examination?
Part 1 contains 300 multiple-choice questions: 200 previously tested questions contribute to the score, and 100 new field-test questions do not. Field-test questions are not identified to candidates. The handbook specifies two groups of 150 questions, each taken during a three-hour session on one day, with a lunch break between sessions. Total examination answering time is six hours; ABU does not specify the break length in these examination descriptions.
ABU: Qualifying Examination (Part 1) · ABU: 2027 Information for Applicants and Candidates
Where is Part 1 delivered, and is it adaptive?
ABU describes an annually administered computer-based examination at Pearson VUE testing centers across the United States. Candidates schedule after Board approval and eligibility notification. ABU describes two examination sessions but does not identify a computer-adaptive algorithm in its examination page or handbook.
ABU: Qualifying Examination (Part 1) · ABU: 2027 Information for Applicants and Candidates
Which item styles and pathology content does ABU describe?
ABU specifies multiple-choice questions but does not state a universal number of answer options for every operational item. ABU excludes questions requiring interpretation of pathology images while retaining pathological findings and principles that affect management. The 20 four-option questions here are independent single-best-answer learning drills, rather than an exact interface simulation or a prediction of examination performance.
Which blueprint weights guide preparation?
The issuer-linked outline assigns Core Urologic Knowledge 20%; Basic Science, with clinical correlation, 5%; Upper and Lower Tract Urinary Obstruction 10%; Urolithiasis 10% plus core; Oncology 25% plus core; Andrology 8%; Urogynecology and Reconstructive Pelvic Surgery, including neurogenic bladder, 12%; and Pediatric Urology 10%. Percentages may vary slightly annually. 'Plus core' denotes overlapping content rather than additional independent weights. The study labels used here are Core urology, Basic science, Urinary obstruction, Urolithiasis, Oncology, Andrology, URPS, and Pediatric urology.
ABU: Exam Content for Qualifying and In-service Examinations
How are the guide, questions and flashcards distributed?
The 60 concepts allocate 12 to Core urology, 3 to Basic science, 6 to Urinary obstruction, 6 to Urolithiasis, 15 to Oncology, 5 to Andrology, 7 to URPS, and 6 to Pediatric urology. Each 20-item question or flashcard set allocates 4, 1, 2, 2, 5, 2, 2, and 2 respectively. Rounding limits exact proportionality. These selections cover every domain but do not replace the full outline, which also includes additional congenital disorders, neoplasms, transplantation, operative complications and allied subjects.
ABU: Exam Content for Qualifying and In-service Examinations
What are the blueprint and handbook dates?
The ABU-linked content PDF applies to Qualifying and In-service Examinations and states no publication, revision or effective date. The separate 2027 Information for Applicants and Candidates is the seventy-fourth edition, revised September 2026. That handbook revision does not establish a revision date for the separate content blueprint.
ABU: Exam Content for Qualifying and In-service Examinations · ABU: 2027 Information for Applicants and Candidates
What are the 2027 examination dates and passing-score policy?
The 2027 handbook lists July 15, 16, 17 and 19, subject to change. The examination page lists the same four dates. ABU describes criterion-referenced scoring with a passing standard adjusted for examination difficulty and no mandatory failure rate. ABU does not publish a fixed percentage-correct passing score in its examination page or handbook.
ABU: 2027 Information for Applicants and Candidates · ABU: Qualifying Examination (Part 1)
This guide addresses initial specialist board certification in urology through ABU Part 1. CertMedbry independently authors the learning materials. ABU sources establish examination scope and format; the cited clinical guidelines and prescribing information support individual clinical principles. EAU recommendations are identified as clinical guidance rather than ABU examination policy.
Outline used: Current ABU-linked Qualifying/In-service examination blueprint, undated with no stated effective date; reviewed alongside the 2027 Information for Applicants and Candidates, seventy-fourth edition, revised September 2026. Verified on 2026-10-09, Asia/Hong_Kong. The workbook label 'American Board of Urology - Qualifying Examination' maps to the official Qualifying (Part 1) Examination; the assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Core urology20%
1.When should asymptomatic bacteriuria be left untreated?
Asymptomatic bacteriuria means bacteria are present without symptoms attributable to urinary infection. A positive culture alone does not establish symptomatic disease. In otherwise stable nonpregnant adults, including many patients with diabetes, long-term catheters or reconstructed urinary tracts, routine treatment offers no established benefit and promotes resistance. The decisive question is whether urinary or systemic symptoms, pregnancy, or an upcoming mucosa-breaching urological procedure create a genuine treatment indication.
Apply it
A nonpregnant woman with well-controlled diabetes has an incidental positive culture but no dysuria, frequency, flank pain or fever. She has no planned urological procedure. Explain why antibiotics are unnecessary and identify symptoms that should prompt reassessment.
Common pitfall: Pyuria, diabetes or an indwelling catheter can make treatment seem compelling. None alone converts asymptomatic colonization into an infection requiring antibiotics.
2.Why does bacteriuria matter before mucosa-breaching urological surgery?
Procedures that enter the urinary tract and breach mucosa can introduce colonizing organisms into tissue and blood. Consequently, asymptomatic bacteriuria becomes a modifiable risk for postoperative infection in this setting. Obtain a preoperative urine culture and use susceptibility-directed treatment when bacteriuria is present. The procedure's tissue disruption, rather than the mere existence of an appointment or urinary device, distinguishes this indication from routine treatment of colonization.
Apply it
A man without urinary symptoms has a positive urine culture before transurethral bladder tumor resection. Recognize the planned mucosal disruption, review susceptibilities and arrange targeted treatment before proceeding with the elective operation safely and appropriately.
Common pitfall: Applying the usual rule against treating asymptomatic bacteriuria without considering the procedure misses a supported exception. Conversely, every diagnostic encounter does not breach mucosa.
3.How do systemic features change the treatment of urinary infection?
Fever, rigors, flank pain or systemic illness suggest infection beyond localized cystitis. Treatment must achieve appropriate tissue and systemic exposure, while evaluation considers obstruction and sepsis. Obtain urine culture in suspected pyelonephritis and adjust therapy to susceptibilities. Nitrofurantoin and oral fosfomycin are unsuitable choices for pyelonephritis, even when useful for selected lower urinary infections. Clinical deterioration or persistent illness should trigger reassessment for a correctable source.
Apply it
A patient treated for dysuria develops fever, vomiting and costovertebral tenderness. Reclassify the illness as a systemic urinary infection, obtain cultures, assess hydration and obstruction, and select treatment appropriate for renal infection rather than isolated cystitis.
Common pitfall: A laboratory report showing urinary susceptibility does not establish adequate treatment at every anatomical site. Drug exposure and disease severity remain essential selection criteria.
4.Which findings support acute bacterial prostatitis?
Abrupt fever, malaise, voiding symptoms and poorly localized pelvic or perineal pain support acute bacterial prostatitis, particularly with a tender prostate. Obtain a midstream urine culture; systemic illness may also warrant blood cultures and parenteral treatment. Avoid prostatic massage because manipulation can provoke bacteremia and sepsis. Persistent fever or failure to improve raises concern for an abscess or inadequate source control rather than simply requiring repeated empirical prescriptions.
Apply it
A febrile man develops dysuria and perineal pain after prostate biopsy. His prostate is tender on gentle examination. Obtain urine and blood cultures, assess systemic severity and avoid attempting to express prostatic secretions for diagnosis.
Common pitfall: Localization cultures used for chronic bacterial prostatitis do not justify massage during acute infection. An elevated PSA during inflammation also does not establish prostate cancer.
5.When does pelvic trauma require urethral evaluation?
Blood at the urethral meatus after pelvic trauma is an important clue to urethral injury. In a stable male patient, retrograde urethrography evaluates urethral continuity and contrast extravasation; flexible cystourethroscopy is another supported diagnostic approach. Define the injury before repeated blind instrumentation. Initial priorities still include resuscitation and safe urinary drainage, with the drainage route and definitive reconstruction determined by injury characteristics and the patient's overall condition.
Apply it
A stable man with a pelvic fracture has meatal blood and cannot void. Arrange retrograde urethrography before routine blind catheter placement, then choose a safe drainage strategy according to urethral continuity and the associated injuries.
Common pitfall: A bladder scan confirms retained urine but cannot exclude urethral disruption. Repeated forceful catheter attempts may worsen injury and delay effective urinary drainage.
6.How must cystography be performed to assess traumatic bladder rupture?
Adequate bladder injury assessment requires active retrograde filling with dilute contrast, using conventional or CT cystography. EAU guidance specifies approximately 300–350 mL in adults when clinically appropriate. Passive accumulation of intravenously excreted contrast, even with a clamped catheter, may fail to distend the bladder sufficiently and miss a rupture. Pelvic fracture with visible hematuria is a strong indication to investigate the bladder using a properly performed study.
Apply it
After a collision, a stable adult has pelvic fractures and gross hematuria. The routine trauma CT shows no leak during its excretory phase. Request dedicated retrograde CT cystography rather than accepting that scan as definitive exclusion.
Common pitfall: The presence of contrast inside the bladder does not prove adequate cystography. The route of filling and sufficient distension determine whether the examination addresses rupture.
7.Which traumatic bladder ruptures require operative repair?
Blunt intraperitoneal bladder rupture generally requires surgical repair because urine entering the peritoneal cavity can cause peritonitis and sepsis. Uncomplicated blunt extraperitoneal rupture can usually heal with continuous catheter drainage. Bladder neck involvement, associated injuries requiring intervention or other complicating features change that approach. Contrast outlining bowel loops identifies intraperitoneal leakage; perivesical extravasation supports an extraperitoneal injury. Anatomical compartment and complexity drive the treatment decision.
Apply it
A cystogram after blunt trauma shows contrast surrounding bowel loops. The patient is stable enough for surgery. Recommend repair with bladder drainage and assessment for associated abdominal injuries rather than catheter drainage as the sole treatment.
Common pitfall: The conservative approach for uncomplicated extraperitoneal injury should not be extended to blunt intraperitoneal rupture. Stability permits planning but does not eliminate the repair indication.
8.Why is hemodynamic stability central to renal trauma management?
Renal injury grade describes anatomy, but hemodynamic status determines the urgency of hemorrhage control. Stable patients with blunt renal trauma are commonly managed nonoperatively with appropriate imaging, monitoring and selective intervention. CT can identify active bleeding, vascular injury and collecting-system involvement. Persistent instability despite resuscitation demands urgent action. Selected arterial bleeding can be treated by embolization, preserving renal tissue while controlling hemorrhage when the clinical situation permits.
Apply it
A stable patient has a renal laceration and contained perirenal hematoma after blunt trauma. Plan monitored nonoperative care with reassessment. If ongoing bleeding develops, use clinical status and imaging to choose embolization or operative hemorrhage control.
Common pitfall: A dramatic CT appearance does not automatically require nephrectomy. Conversely, an anatomical grade should never outweigh persistent shock or evidence of uncontrolled ongoing bleeding.
9.Which presentation makes penile fracture a surgical diagnosis?
Penile fracture is rupture of the cavernosal tunica albuginea during erection. A cracking sound, immediate detumescence, pain and rapidly developing swelling after bending trauma are characteristic. A convincing presentation warrants prompt surgical exploration and repair; imaging is useful when the diagnosis is uncertain. Meatal blood, visible hematuria or inability to void should raise concern for associated urethral injury and prompt appropriate urethral evaluation alongside fracture management.
Apply it
During intercourse, a patient hears a snap followed by immediate loss of erection and marked penile swelling. Arrange prompt surgical assessment and repair. Ask specifically about hematuria and voiding difficulty to identify a possible associated urethral injury.
Common pitfall: Treating a classic fracture as a simple superficial hematoma delays repair. However, nonspecific bruising without the characteristic history can warrant imaging before operative commitment.
10.How can fluoroscopic exposure be reduced during stone procedures?
Radiation protection begins by avoiding unnecessary exposure and minimizing the exposure needed for a useful image. During fluoroscopic stone procedures, use brief or pulsed screening, tight collimation, appropriate low-dose settings and saved images when feasible. Ultrasound guidance can reduce fluoroscopy in selected procedures. Patient exposure and staff exposure are related, so deliberate imaging technique benefits both. Image quality must remain adequate to guide access and recognize complications safely.
Apply it
During ureteroscopy, repeated screening is being used to confirm an unchanged wire position. Use stored images and brief targeted checks, collimate the field and select appropriate low-dose settings while preserving sufficient visualization for safe instrument advancement.
Common pitfall: Protective garments do not substitute for reducing unnecessary fluoroscopy. Equally, minimizing exposure must not mean advancing instruments without the visualization needed for procedural safety.
11.How are sensitivity and specificity calculated correctly?
Sensitivity is the proportion of people with disease who test positive: true positives divided by true positives plus false negatives. Specificity is the proportion without disease who test negative: true negatives divided by true negatives plus false positives. Start by identifying disease status using the reference standard, then choose the relevant denominator. Predictive values instead begin with test-result groups and answer different clinical questions about the meaning of an observed result.
Apply it
Among 80 patients with reference-standard disease, 68 test positive. Among 120 without disease, 102 test negative. Calculate sensitivity as 68/80 and specificity as 102/120: both equal 85%, despite different denominators in this example.
Common pitfall: Dividing true positives by everyone testing positive calculates positive predictive value. A correct numerator paired with the wrong denominator answers a different diagnostic question.
12.What makes consent a meaningful clinical decision?
Meaningful consent requires communication about the indication, expected benefits, material risks and reasonable alternatives in a way the patient can understand. The ABU ethics framework prioritizes patient welfare, autonomy and honest communication. A signed form records a process but cannot replace it. When a proposed operation conflicts with a patient's goals or preferences, clarify those concerns before proceeding and document the agreed plan, including appropriate alternatives and postoperative arrangements.
Apply it
A patient scheduled for surgery says preservation of sexual function matters more than rapid symptom improvement. Revisit the expected functional tradeoffs and alternatives, check understanding and confirm that the proposed operation still matches the patient's informed preferences.
Common pitfall: Technical appropriateness does not establish patient agreement. Describing only benefits or treating a signature as proof of understanding undermines the autonomy central to informed consent.
Basic science5%
13.How does mirabegron improve storage symptoms?
Mirabegron stimulates beta-3 adrenergic receptors and relaxes detrusor smooth muscle during bladder filling, increasing storage capacity. This differs from blocking muscarinic receptors or relaxing the prostatic outlet. The prescribing information warns that mirabegron can increase blood pressure and recommends periodic monitoring. It is not recommended with severe uncontrolled hypertension, defined as systolic pressure at least 180 mm Hg or diastolic pressure at least 110 mm Hg.
Apply it
A patient with urgency incontinence wants an alternative after troublesome antimuscarinic dry mouth. Explain the beta-3 storage mechanism, measure blood pressure and avoid starting mirabegron while a repeated reading remains 184/112 mm Hg at assessment.
Common pitfall: Fewer antimuscarinic effects do not mean an absence of important precautions. Blood pressure and possible retention in susceptible patients still require clinical attention.
DailyMed: Mirabegron Extended-Release Tablets Prescribing Information
14.How does ureteral blood supply influence reconstruction after distal injury?
A distal ureteral injury can compromise the blood supply of the remaining distal segment. This anatomical vulnerability favors ureteral reimplantation into the bladder over an anastomosis that depends on damaged distal tissue. Reconstruction requires viable tissue and a tension-free connection. A psoas hitch brings the bladder toward the ureter to bridge a gap; a Boari bladder flap can bridge a longer mid-to-distal defect when appropriate. Defect location and viable length determine which reconstruction is feasible.
Apply it
A distal ureter is injured during pelvic surgery, and the remaining distal tissue appears devascularized. Plan reimplantation using healthy ureter; add bladder mobilization or a psoas hitch if direct reimplantation would create tension.
Common pitfall: Preserving a visibly ischemic segment to achieve an anatomically short repair can produce leakage or later stricture. A technically connected anastomosis still requires adequate perfusion and freedom from tension.
ABU: Exam Content for Qualifying and In-service Examinations · EAU Guidelines on Urological Trauma
15.Why can alkaline urine coexist with a need for alkali treatment in distal renal tubular acidosis?
Distal renal tubular acidosis impairs renal proton secretion, allowing systemic metabolic acidosis despite inadequately acidified urine. Calcium phosphate stones, hypocitraturia and sometimes hypokalemia provide clinical clues. EAU guidance recommends alkaline citrate to correct the systemic acid-base disorder and improve urinary citrate, even though urine is already alkaline. Follow serum bicarbonate, potassium and urinary risk factors. If hypercalciuria persists after acid-base correction, a thiazide can be considered.
Apply it
A recurrent calcium phosphate stone former has low serum bicarbonate, hypokalemia and persistently alkaline urine without urease-producing infection. Evaluate distal renal tubular acidosis and use monitored alkali treatment to correct systemic acidosis.
Common pitfall: Urinary alkalinity does not establish adequate systemic bicarbonate. Avoid withholding indicated alkali solely because urine pH is high; monitor the overall biochemical response.
ABU: Exam Content for Qualifying and In-service Examinations · EAU Urolithiasis Guidelines: Metabolic Evaluation and Recurrence Prevention
Urinary obstruction10%
16.How does the bladder outlet obstruction index classify male voiding?
In male pressure-flow assessment, the bladder outlet obstruction index is detrusor pressure at maximum flow minus twice maximum flow: BOOI = PdetQmax − 2Qmax. Values above 40 indicate obstruction, 20–40 are equivocal, and below 20 are unobstructed. High pressure with low flow supports outlet resistance; low pressure with low flow suggests detrusor weakness. Low flow or a large residual alone cannot distinguish these mechanisms; an inadequately filled bladder can also produce misleading flow results.
Apply it
A man has PdetQmax of 66 cm H2O and Qmax of 8 mL/s. Calculate BOOI as 66 − 16 = 50, supporting obstruction. Check study quality and interpret contractility, anatomy and symptoms before counseling about surgery.
Common pitfall: Subtracting Qmax only once or using maximum vesical pressure gives the wrong index. Residual volume measures incomplete emptying without proving obstruction, and male BOOI thresholds should not be transferred uncritically to women.
17.How should noncalculous upper-tract obstruction after ureteral injury be evaluated and relieved?
Delayed ureteral injury or stricture can present with hydronephrosis, infection, flank pain or impaired renal function without a stone. CT urography evaluates the ureter and delayed contrast leakage; retrograde or antegrade studies can define an uncertain lesion. Establish drainage with a ureteral stent or nephrostomy when renal function or infection requires intervention. Delayed injuries are often approached initially by stenting, with reconstruction if endourological treatment fails.
Apply it
Following pelvic surgery, a patient develops unilateral hydronephrosis and fever without a calculus. Assess for ureteral injury, begin infection treatment and urgently secure drainage rather than treating the presentation as uncomplicated pyelonephritis.
Common pitfall: Absence of hematuria or a stone does not exclude consequential ureteral obstruction. Drainage treats the immediate threat but does not establish that a persistent stricture has been definitively corrected.
ABU: Exam Content for Qualifying and In-service Examinations · EAU Guidelines on Urological Trauma
18.What do alpha-blockers change in male lower urinary tract symptoms?
Alpha-blockers reduce alpha-adrenergic smooth-muscle tone in the prostate and bladder neck, improving symptoms relatively quickly. They do not substantially shrink the prostate or provide the established long-term reduction in retention and surgery associated with 5-alpha-reductase inhibitors. Treatment selection should account for blood-pressure effects, dizziness, ejaculatory adverse effects and planned cataract surgery. Symptom relief reflects reduced dynamic resistance rather than reversal of all anatomical or detrusor contributors to voiding dysfunction.
Apply it
A man wants prompt relief of bothersome voiding symptoms and has no complication requiring surgery. Discuss an alpha-blocker, review orthostatic symptoms and cataract plans, and explain that improvement does not mean the prostate has become smaller.
Common pitfall: Rapid improvement can be mistaken for prevention of BPH progression. A patient with renal consequences or recurrent refractory retention may need a different management strategy.
19.When does a 5-alpha-reductase inhibitor offer a distinct benefit?
Five-alpha-reductase inhibitors reduce conversion of testosterone to dihydrotestosterone, producing gradual prostate shrinkage. They are most useful in men with enlargement and increased progression risk, rather than as rapid relief for every patient with LUTS. Their benefits include reduced risk of acute retention and BPH-related surgery over time. PSA commonly falls by about half after sustained treatment, so establish a treatment baseline and investigate a confirmed subsequent rise appropriately.
Apply it
A man with an enlarged prostate and progressive symptoms seeks treatment that addresses future retention risk. Discuss the delayed action and sexual adverse effects of a 5-alpha-reductase inhibitor, and document how PSA will be interpreted during follow-up.
Common pitfall: Judging efficacy after only a few days ignores the mechanism. Interpreting a treatment-suppressed PSA against an untreated baseline can also provide false reassurance.
20.Which consequences of benign prostatic obstruction favor surgery?
Surgery is generally indicated when benign prostatic obstruction causes recurrent or refractory retention, recurrent infection, bladder stones, treatment-resistant prostatic bleeding or upper tract dilation with or without renal impairment. These consequences carry more weight than symptom scores alone. Confirm that the proposed mechanism explains the complication, then select an operation using prostate anatomy, patient priorities and procedural suitability. Persistent bothersome symptoms despite conservative or medical treatment provide another reason to discuss intervention.
Apply it
A man taking medical therapy develops repeated retention and bilateral upper tract dilation attributed to prostatic obstruction. Discuss operative relief and assess renal function rather than simply escalating symptom medication because his reported symptom score is moderate.
Common pitfall: A tolerable symptom score does not neutralize organ-threatening obstruction. Conversely, an incidental enlarged prostate does not prove that every renal abnormality has a prostatic cause.
21.When should urethroplasty replace repeated endoscopic stricture treatment?
Endoscopic dilation or direct vision internal urethrotomy can be appropriate for a selected primary, short, nonobliterative bulbar stricture. Recurrence, greater length and unfavorable location reduce the likelihood of durable endoscopic success. Repeated procedures can increase stricture complexity and postpone definitive reconstruction. EAU guidance advises against repetitive treatment beyond two endoscopic attempts when urethroplasty is viable. Define length, site and prior treatment before choosing a reconstructive approach with the patient.
Apply it
A fit man has another recurrence of a bulbar stricture after three urethrotomies. Review the urethral anatomy and discuss urethroplasty as a durable strategy, including recovery and functional considerations, rather than scheduling another routine incision.
Common pitfall: Temporary improvement after each incision does not establish durable cure. Endoscopic treatment remains useful in selected circumstances, but recurrent disease requires reassessing its purpose and limitations.
EAU Urethral Stricture Guidelines: Disease Management in Males
Urolithiasis10% + core
22.Why must an infected obstructed collecting system be drained urgently?
An obstructed collecting system with sepsis requires source control as well as antimicrobial treatment. Urgently decompress using a ureteral stent or percutaneous nephrostomy, obtain appropriate cultures and begin antibiotics immediately. Either drainage method can be effective; anatomy, access and clinical circumstances guide selection. Delay definitive stone fragmentation or extraction until sepsis has resolved. Manipulating an infected obstructed system to achieve immediate stone clearance can worsen systemic infection and increase procedural risk.
Apply it
A patient has fever, hypotension and a proximal ureteral stone with hydronephrosis. Start resuscitation and antibiotics while arranging urgent drainage. Plan definitive stone treatment after infection control rather than combining decompression with elective-style prolonged stone fragmentation.
Common pitfall: Antibiotics alone do not correct the obstructed source. A small stone or anticipated spontaneous passage does not justify waiting when obstruction and sepsis coexist.
23.How do stone burden and anatomy guide procedural selection?
Stone treatment balances clearance, invasiveness and repeat-procedure risk. Percutaneous nephrolithotomy is generally first-line treatment for renal stones larger than 2 cm. Shock-wave lithotripsy becomes less effective with unfavorable stone characteristics or lower-pole anatomy, while ureteroscopy can provide an alternative but may require staged treatment for large burdens. Incorporate location, density, collecting-system anatomy, infection and bleeding risk rather than selecting a procedure from stone diameter alone in every case.
Apply it
A fit adult has a 2.8 cm renal stone without active infection. Discuss percutaneous treatment as the usual first-line approach, then assess access anatomy and bleeding risk. Explain why less invasive options could require multiple treatment sessions.
Common pitfall: The least invasive single procedure does not always produce the least overall treatment burden. Untreated infection must be controlled before elective stone clearance is attempted.
24.Which imaging sequence is appropriate for suspected stones during pregnancy?
Ultrasound is the first imaging choice for suspected renal colic during pregnancy, but physiological collecting-system dilation can mimic obstruction. MRI is a second-line option when clarification is needed; gadolinium is not routinely recommended. Low-dose CT is reserved as a last-line diagnostic option when the remaining uncertainty would materially affect care. Pregnancy does not justify withholding a clearly necessary study, but radiation exposure and diagnostic benefit require deliberate justification and multidisciplinary discussion.
Apply it
A pregnant patient has persistent unilateral flank pain and an inconclusive ultrasound. She remains stable without infection. Consider MRI to clarify obstruction before proceeding to an invasive intervention or choosing low-dose CT as a justified last-line investigation.
Common pitfall: Hydronephrosis during pregnancy does not automatically establish an obstructing stone. Conversely, repeatedly inconclusive imaging should not prevent a justified investigation when management depends on the answer.
25.How should recurrent stone risk be evaluated metabolically?
Stone composition and recurrence risk guide metabolic evaluation. All stone formers need a basic assessment and reliable stone analysis when material is available; high-risk patients warrant specific investigation. EAU guidance uses two consecutive 24-hour urine collections to characterize factors such as volume, calcium, oxalate, citrate, uric acid and pH. Collect under representative conditions after the acute episode has settled. Interpret abnormalities together because multiple contributors commonly interact to increase urinary supersaturation.
Apply it
A patient with repeated calcium stones submits one unusually low-volume collection during an acute vomiting illness. Arrange representative collections after recovery, assess collection adequacy and use the combined biochemical pattern to design prevention and evaluate subsequent response.
Common pitfall: A single atypical collection can misdirect prevention. Stone labels alone also do not establish the dominant metabolic abnormality or justify identical drug treatment for every patient.
EAU Urolithiasis Guidelines: Metabolic Evaluation and Recurrence Prevention
26.Why can calcium with meals help enteric hyperoxaluria?
Fat malabsorption increases intestinal oxalate availability and absorption, promoting calcium oxalate stones. Bowel resection, malabsorptive bariatric surgery and Crohn's disease are important clues. Calcium taken with meals binds oxalate within the intestinal lumen, reducing its absorption. Prevention also addresses excess fat and oxalate intake, diarrheal fluid loss and associated hypocitraturia. The location and timing of calcium exposure explain why eliminating dietary calcium can worsen this form of stone risk.
Apply it
A patient with ileal resection has recurrent calcium oxalate stones, diarrhea and high urine oxalate. Recommend calcium with meals alongside dietary and fluid measures, and assess citrate rather than advising indiscriminate restriction of all calcium intake.
Common pitfall: The calcium content of the stone can tempt patients to remove dietary calcium. In enteric hyperoxaluria, that may leave more intestinal oxalate available for absorption.
EAU Urolithiasis Guidelines: Metabolic Evaluation and Recurrence Prevention
27.What links urease-producing organisms to infection stones?
Urease-producing organisms split urea, increasing ammonia and making urine alkaline. This environment promotes struvite and other infection-associated mineral precipitation. Culture findings, urine pH and stone analysis are therefore complementary diagnostic clues. Management emphasizes complete stone removal when feasible and appropriate antimicrobial treatment because retained infected material can sustain recurrence. Mixed infection stones may also conceal metabolic abnormalities, so specific metabolic evaluation can be useful after removal and infection control.
Apply it
A patient has recurrent Proteus infection, persistently alkaline urine and a branching renal calculus. Suspect an infection stone, obtain cultures and plan infection control with stone clearance, then evaluate remaining metabolic risks once the acute process is controlled.
Common pitfall: Branching shape alone does not prove struvite composition. Antibiotics without addressing infected residual stone material may leave the underlying reservoir for further infection and growth.
EAU Urolithiasis Guidelines: Metabolic Evaluation and Recurrence Prevention
Oncology25% + core
28.Why is partial nephrectomy preferred for suitable T1 renal tumors?
Partial nephrectomy removes the tumor while preserving functioning renal parenchyma. For suitable T1 renal tumors, it provides established oncological control and better preservation of renal function than removing the entire kidney. Nephron preservation is especially important with chronic kidney disease, a solitary kidney or bilateral tumors. Assess technical feasibility and perioperative risk; the recommendation does not mean every tumor can be safely resected partially regardless of location, complexity or extent.
Apply it
A patient with chronic kidney disease has a 3 cm peripheral enhancing renal mass amenable to resection. Discuss partial nephrectomy as a way to obtain oncological control while limiting additional nephron loss, incorporating operative complexity and personal priorities.
Common pitfall: A normal opposite kidney does not make renal preservation irrelevant. Equally, preserving parenchyma should not require accepting an unsafe operation or inadequate tumor treatment.
29.When is adrenalectomy justified during renal cancer surgery?
Ipsilateral adrenalectomy is selective rather than routine during surgery for renal cell carcinoma. Imaging or intraoperative evidence of adrenal involvement supports removal; an upper-pole renal tumor by itself does not. Preserving a normal adrenal avoids unnecessary organ removal without sacrificing an established survival benefit. The key distinction is between anatomical proximity and actual suspicion of invasion or metastasis, interpreted alongside the tumor's overall stage and the operative findings.
Apply it
A patient requires radical nephrectomy for a large upper-pole tumor, but imaging shows a normal adrenal and surgery reveals no involvement. Preserve the adrenal unless new findings create a specific oncological reason to remove it.
Common pitfall: Upper-pole location can make routine adrenal removal seem intuitive. Location alone is insufficient evidence of involvement and should not replace review of imaging and operative findings.
30.Why should renal mass biopsy precede thermal ablation?
An enhancing renal mass is not automatically malignant. Tissue diagnosis before thermal ablation helps avoid treating a benign lesion and informs surveillance and counseling. EAU guidance recommends percutaneous biopsy before, rather than concomitantly with, ablation. Ablation may suit selected patients requiring treatment who are unfit for surgery, but it requires discussion of oncological evidence and follow-up. Surveillance remains an alternative for selected small masses when immediate treatment offers limited benefit.
Apply it
A medically frail patient with a small renal mass is considering cryoablation. Obtain a biopsy in advance, discuss what benign or nondiagnostic findings would change, and compare ablation with surveillance in light of competing health risks.
Common pitfall: Performing biopsy only as ablation begins removes the opportunity to reconsider treatment using the result. Imaging enhancement alone does not establish the lesion's histological identity.
31.Which patients suit active surveillance, and what initial confirmation and subsequent monitoring does it require?
Common selection criteria include Grade Group 1, cT1c–cT2a disease, PSA below 10 ng/mL and life expectancy exceeding ten years. MRI, PSA density and biopsy extent refine suitability; PSA density below 0.15 ng/mL/cc is favorable but not an absolute eligibility threshold. If selection rests on systematic biopsy without prebiopsy MRI, obtain MRI before confirmatory sampling and arrange confirmatory biopsy within six to twelve months to exclude initial undersampling. Adequate upfront combined systematic and MRI-targeted sampling can remove the need for a separate confirmatory biopsy. Subsequent surveillance includes PSA at least every six months, generally annual DRE and repeat biopsy usually every two to three years. Serial DRE may be omitted when MRI remains stable. Selected low-risk patients with stable MRI and persistently low PSA density below 0.15 may omit routine repeat biopsy after individualized assessment; stable MRI alone is insufficient.
Apply it
A healthy man with Grade Group 1, cT1c disease and PSA 5.2 ng/mL diagnosed by systematic biopsy without prior MRI needs MRI and confirmatory biopsy within six to twelve months, rather than waiting two to three years for his first reassessment biopsy. Sample suspicious MRI findings during confirmation. During subsequent surveillance, a PSA doubling time shorter than three years warrants MRI and repeat biopsy to investigate possible progression.
Common pitfall: Initial confirmation addresses cancer missed or undergraded at diagnosis; later surveillance detects reclassification over time. A reassuring MRI does not automatically eliminate biopsy. MRI progression requires biopsy confirmation before changing treatment, and treatment decisions should rest on biopsy progression rather than PSA or MRI changes alone. Active surveillance preserves the option of curative treatment and differs from symptom-directed watchful waiting.
32.How does watchful waiting differ from active surveillance?
Watchful waiting is a conservative strategy for patients in whom curative treatment is not appropriate, commonly because life expectancy is limited by age and comorbidity. Intervention is directed at symptomatic or imminent clinical progression. Active surveillance instead uses structured monitoring with possible delayed curative treatment. The distinguishing feature is treatment intent, not simply how often PSA is checked. Estimate competing mortality and functional status rather than making the choice from chronological age alone.
Apply it
An older man with severe irreversible comorbidity has asymptomatic low-risk prostate cancer and limited life expectancy. Discuss watchful waiting with symptom-directed care, explaining why repeated biopsies aimed at preserving a curative option may offer little meaningful benefit.
Common pitfall: Calling every untreated localized cancer 'active surveillance' obscures intent. A patient who would never pursue curative treatment may be better served by watchful waiting.
33.When should a PSA rise during surveillance change management?
EAU clinical guidance recommends MRI and repeat biopsy for rising PSA with a PSA doubling time below three years. PSA kinetics trigger investigation rather than independently establishing progression. MRI progression likewise requires biopsy reassessment before treatment changes. Decisions to leave surveillance ordinarily depend on biopsy progression, interpreted with health status and preferences.
Apply it
A man on surveillance develops a confirmed PSA doubling time of two years. Arrange MRI and repeat biopsy before recommending definitive treatment.
Common pitfall: A rapid PSA rise requires action, but neither PSA nor MRI progression alone ordinarily justifies abandoning surveillance.
34.Which bladder tumor findings require a second resection?
A second transurethral bladder tumor resection clears residual disease and corrects understaging. EAU indications include an incomplete initial resection, uncertainty about completeness, T1 disease, or absent detrusor muscle except in specified low-grade Ta and primary CIS settings. When indicated, repeat resection is generally performed within two to six weeks and includes the original site. The presence of muscle in an initial T1 specimen does not remove the repeat-resection indication.
Apply it
An initial resection shows high-grade T1 urothelial carcinoma with detrusor muscle present and uninvolved. Arrange repeat resection of the original site to assess residual tumor and staging before finalizing subsequent treatment discussions with the patient.
Common pitfall: Visible completeness and muscle sampling do not eliminate the residual-disease risk in T1 cancer. Intravesical treatment should not substitute for indicated staging and completion resection.
EAU Non-muscle-invasive Bladder Cancer Guidelines: Diagnosis
35.How should urinary cytology be interpreted and localized?
Urinary cytology detects exfoliated urothelial cells and is most useful for high-grade disease, including carcinoma in situ. Its lower sensitivity for low-grade tumors means a negative result cannot exclude a visible lesion or replace cystoscopy. Positive cytology can originate anywhere along the urothelial tract. With positive cytology and negative cystoscopy, exclude upper tract disease, occult bladder CIS using mapping or photodynamic-guided biopsies, and prostatic urethral tumor in men.
Apply it
A man has repeated high-grade cytology but normal white-light cystoscopy. Evaluate the upper tracts and arrange appropriate bladder biopsies and prostatic urethral sampling rather than declaring the cytology false-positive.
Common pitfall: Negative cytology does not exclude low-grade papillary cancer. Positive cytology does not localize its source, and flat CIS may escape ordinary white-light inspection.
EAU Non-muscle-invasive Bladder Cancer Guidelines: Diagnosis
36.What distinguishes definitive treatment options for localized muscle-invasive bladder cancer?
EAU [clinical guidance](https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer/chapter/disease-management) recommends radical cystectomy with pelvic lymph node dissection for suitable T2–T4a N0M0 disease. Selected patients can pursue bladder preservation through maximal TURBT followed by concurrent chemoradiation. Favorable features include a solitary tumor, absence of extensive or multifocal CIS and good bladder function. Assess perioperative systemic treatment before surgery: cisplatin-based combination chemotherapy improves survival, and eligible patients may receive perioperative gemcitabine/cisplatin with durvalumab.
Apply it
A fit patient with cT2N0M0 urothelial cancer needs discussion of cystectomy, systemic-treatment eligibility and a suitable trimodality alternative. Bladder preservation requires surveillance and access to salvage cystectomy for invasive recurrence.
Common pitfall: TURBT or intravesical therapy alone does not provide the usual definitive treatment for muscle-invasive disease. Carboplatin is not an established substitute for neoadjuvant cisplatin.
ABU: Exam Content for Qualifying and In-service Examinations
37.Why is the inguinal approach standard for a suspected testicular malignancy?
A suspicious intratesticular mass is assessed with ultrasound and serum tumor markers, followed in the usual malignant germ-cell setting by radical inguinal orchiectomy with high cord division. The inguinal approach avoids scrotal violation, which is associated with increased local recurrence risk. Routine transscrotal biopsy is therefore inappropriate. Selected testis-sparing situations require specialist planning and do not justify treating every solid mass like an ordinary superficial lesion suitable for office biopsy.
Apply it
A young adult has a solid intratesticular mass and a normal opposite testis. Obtain preoperative markers, discuss fertility preservation and plan inguinal orchiectomy rather than arranging a transscrotal needle biopsy to establish the diagnosis first routinely.
Common pitfall: Normal markers do not exclude testicular cancer. The usual desire to biopsy before surgery must be adapted to the oncological principles of a suspicious testicular mass.
38.Why does substantial AFP elevation challenge a pure seminoma diagnosis?
Pure seminoma does not account for substantial AFP production. A convincing AFP elevation in a patient labeled as having seminoma should prompt assessment for a nonseminomatous component and other explanations for AFP elevation. By contrast, hCG can be elevated in seminoma. Reconcile pathology, marker magnitude and marker behavior before assigning a treatment category. Modest stable elevations require careful interpretation and should not automatically trigger the same conclusion as a substantial rising AFP.
Apply it
Orchiectomy pathology is reported as seminoma, but AFP is markedly elevated and remains abnormal on confirmation. Request pathological review and assess the marker source, recognizing that the findings cannot simply be accepted as uncomplicated pure seminoma.
Common pitfall: Confusing AFP with hCG erases an important discriminator. A minor stable AFP abnormality also deserves contextual evaluation rather than automatic reclassification without considering alternative causes.
39.How do tumor-marker half-lives inform testicular cancer staging?
AFP, hCG and LDH are measured before and after orchiectomy because marker behavior contributes to staging and prognosis. AFP has a serum half-life of approximately five to seven days; hCG has a half-life of roughly one to three days. An initially elevated marker may therefore remain detectable during expected clearance. Failure to decline appropriately or a subsequent rise suggests persistent disease, while normalization does not exclude marker-negative metastases elsewhere.
Apply it
AFP is still elevated shortly after orchiectomy but has fallen at a rate consistent with its expected half-life. Continue serial measurement and complete staging rather than declaring persistent disease from that isolated postoperative value alone without considering kinetics.
Common pitfall: An abnormal early postoperative result is not automatically treatment failure. Conversely, normalized markers cannot replace imaging because some metastatic disease produces no measurable marker elevation.
40.What operation and bladder-recurrence prevention address high-risk upper tract urothelial carcinoma?
Radical nephroureterectomy removes the kidney, entire ureter and bladder cuff for suitable high-risk nonmetastatic upper tract urothelial carcinoma. Invasive renal-pelvic disease with a functioning opposite kidney favors this approach. Kidney-sparing treatment requires carefully selected indications. After surgery, a single intravesical chemotherapy instillation reduces bladder recurrence in appropriate patients without previous bladder cancer; confirm safe bladder integrity before administration.
Apply it
A fit patient has invasive high-grade renal-pelvic cancer and preserved contralateral function. Plan complete nephroureterectomy and assess eligibility for postoperative bladder instillation after ensuring there is no suspected leakage.
Common pitfall: Leaving the intramural ureter compromises complete extirpation. Intravesical chemotherapy cannot replace systemic treatment or be administered safely into a leaking bladder.
EAU Upper Tract Urothelial Carcinoma Guidelines: Disease Management
41.When does upper tract urothelial carcinoma require postoperative systemic treatment?
EAU guidance recommends adjuvant platinum-based chemotherapy after nephroureterectomy for eligible patients with pT2–T4 and/or node-positive disease. Pathological invasion or nodal involvement identifies recurrence risk beyond the urothelial surface. Assess postoperative renal function and overall treatment fitness; renal loss can affect cisplatin eligibility. This decision is distinct from postoperative intravesical chemotherapy, which targets bladder recurrence.
Apply it
Nephroureterectomy shows pT3N0 urothelial carcinoma. Arrange systemic-treatment assessment using the pathological stage, kidney function and comorbidity rather than assuming complete visible resection eliminates recurrence risk.
Common pitfall: Intravesical chemotherapy does not treat occult systemic disease. Evaluate platinum eligibility rather than automatically prescribing or dismissing cisplatin after renal surgery.
EAU Upper Tract Urothelial Carcinoma Guidelines: Disease Management
42.Which metabolic and mechanical complications require follow-up after intestinal urinary diversion?
Diversion stones can reflect stasis, mucus, foreign material, urease-producing infection and metabolic abnormalities. Assess emptying and drainage as well as removing calculi. EAU [follow-up guidance](https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer/chapter/followup) also identifies metabolic acidosis, vitamin B12 deficiency, renal deterioration and ureteroenteric strictures as important late complications. Chronic acidosis contributes to bone loss. Measure B12 annually after bowel diversion and assess acid-base status and renal function when bicarbonate falls or unexplained weakness develops.
Apply it
A neobladder patient has recurrent stones, incomplete emptying and low serum bicarbonate. Evaluate reservoir drainage, obstruction, kidney function and metabolic acidosis rather than treating bacteriuria as the sole explanation.
Common pitfall: Stone extraction alone leaves persistent causes untreated. Altered bowel anatomy also changes procedural access, requiring imaging to avoid intervening bowel during percutaneous treatment.
ABU: Exam Content for Qualifying and In-service Examinations · EAU Guidelines on Urolithiasis: Guidelines · EAU Guidelines on Neuro-urology
Andrology8%
43.Why are PDE5 inhibitors contraindicated with nitrates?
PDE5 inhibitors reduce degradation of cyclic GMP, amplifying the smooth-muscle relaxation pathway involved in erection. Organic nitrates and other nitric oxide donors increase cyclic GMP production. Combining the pathways can produce excessive vasodilation and unpredictable, dangerous hypotension. Review prescribed nitrates, as-needed nitroglycerin and recreational nitrites before treatment. Stable cardiovascular disease alone is not the same contraindication, but cardiovascular fitness for sexual activity and the patient's medication regimen still need assessment.
Apply it
A man taking long-acting nitrate therapy requests sildenafil. Explain the interaction and select a suitable alternative approach after cardiovascular assessment rather than assuming that lowering the sildenafil dose or separating the tablets by a few hours makes use safe.
Common pitfall: As-needed nitrate use still matters even when the patient has taken none today. Recreational nitrites can be overlooked unless the medication and substance history is explicit.
EAU Sexual and Reproductive Health Guidelines: Erectile Dysfunction
44.How should apparent PDE5-inhibitor failure be reassessed?
An apparent nonresponse may reflect incorrect use rather than pharmacological failure. Review the prescribed dose, timing, sexual stimulation, number of appropriate attempts and medication authenticity. High-fat meals can delay absorption of sildenafil, vardenafil and avanafil. Assess relevant comorbidity and investigate androgen deficiency when indicated. Education can restore benefit in some patients, so verify adequate use before moving to injections or prosthetic surgery while respecting the patient's preferences and treatment goals.
Apply it
A patient reports that sildenafil failed twice, each time immediately after a heavy meal and without sexual stimulation. Correct the timing and administration expectations, review safety and arrange reassessment before concluding that oral treatment cannot work for him.
Common pitfall: PDE5 inhibition does not automatically produce an erection without stimulation. Escalating to an invasive treatment before checking use can mistake a correctable administration problem for refractory disease.
EAU Sexual and Reproductive Health Guidelines: Erectile Dysfunction
45.How is symptomatic androgen deficiency confirmed and localized?
Diagnosis requires compatible clinical features and consistently low testosterone. Obtain morning fasting total testosterone using a reliable assay and confirm a low result on another occasion. Consider illness, medications, sleep and altered sex hormone-binding globulin; free testosterone assessment can clarify selected cases. LH stimulates Leydig-cell testosterone production, while FSH supports Sertoli-cell function. Low testosterone with elevated gonadotropins suggests primary testicular dysfunction; low or inappropriately normal gonadotropins suggest hypothalamic or pituitary dysfunction.
Apply it
A man with reduced libido has one low afternoon testosterone result during acute illness. Repeat morning fasting testing after recovery, then interpret confirmed results with symptoms and gonadotropins before recommending treatment.
Common pitfall: A laboratory-normal LH may be inappropriate when testosterone is low. One poorly timed testosterone result or nonspecific fatigue alone does not establish permanent androgen deficiency.
EAU Sexual and Reproductive Health Guidelines: Male Hypogonadism
46.Why can testosterone treatment impair fertility?
Exogenous testosterone suppresses hypothalamic-pituitary gonadotropin secretion through negative feedback. Reduced LH and FSH undermine intratesticular testosterone support and spermatogenesis even while circulating testosterone improves. Therefore, testosterone therapy is inappropriate for men actively seeking fertility. Establish reproductive goals before prescribing and determine the cause of androgen deficiency. In selected central hypogonadism, gonadotropin-based treatment can support testosterone production and sperm production rather than suppressing the reproductive axis further with replacement.
Apply it
A man with low testosterone and an active plan to conceive requests testosterone injections to improve his semen count. Explain why replacement may worsen sperm production and arrange cause-directed reproductive evaluation before choosing a fertility-preserving treatment approach.
Common pitfall: Normalizing serum testosterone does not guarantee normal intratesticular conditions. Improved libido can coexist with markedly reduced sperm production, so symptoms alone cannot monitor fertility effects.
EAU Sexual and Reproductive Health Guidelines: Male Hypogonadism · EAU Sexual and Reproductive Health Guidelines: Male Infertility
47.When does absence of the vas deferens require genetic counseling?
Congenital bilateral absence of the vas deferens is a clue to obstructive azoospermia and CFTR-related disease, even without classic pulmonary cystic fibrosis. Evaluate CFTR variants and provide reproductive genetic counseling. Partner testing matters because assisted reproduction can transmit relevant variants to offspring. Testicular sperm production may be preserved despite absent sperm in the ejaculate. Unilateral vasal absence also raises renal-anomaly considerations, so anatomical and genetic findings should guide the complete evaluation.
Apply it
An azoospermic man has normal-sized testes and bilaterally absent vasa. Before sperm retrieval with intracytoplasmic sperm injection, arrange CFTR evaluation and counseling, including appropriate partner testing, rather than treating the obstruction as solely a technical sperm-delivery problem.
Common pitfall: Absence of respiratory symptoms does not exclude CFTR-related reproductive disease. Successful sperm retrieval bypasses obstruction but does not remove the couple's inherited reproductive risks.
EAU Sexual and Reproductive Health Guidelines: Male Infertility
URPS12%
48.Which symptoms distinguish stress from urgency urinary incontinence?
Stress urinary incontinence is leakage associated with effort, exertion, coughing or sneezing. Urgency urinary incontinence is leakage associated with a compelling need to void. Both can coexist as mixed incontinence. Initial evaluation combines a precise symptom history, examination, urinalysis and residual assessment; a cough stress test helps demonstrate stress leakage. Continuous leakage, hematuria, pain or neurological features suggest additional diagnoses and should prevent automatic assignment to uncomplicated stress or urgency pathways.
Apply it
A woman leaks during running and coughing but denies preceding urgency. Perform an appropriate cough stress test and assess other urinary symptoms, urinalysis and emptying before discussing treatment directed at stress incontinence and her individual goals.
Common pitfall: The word 'incontinence' does not identify a mechanism. Treating exertional leakage as overactive bladder solely because both involve pads can miss the principal symptom pattern.
49.How does a bladder diary clarify frequency and nocturia?
A bladder diary records intake, voiding times, voided volumes, urgency and leakage, making symptom patterns measurable. EAU guidance recommends at least three days for assessment of female LUTS. Frequent small voids suggest a different problem from frequent large voids with high total urine production. Nighttime volumes can further clarify nocturia mechanisms. Diaries also provide a baseline for treatment response, although substantial unmeasured leakage can limit the accuracy of calculated total output.
Apply it
A woman reports urinating every hour and requests stronger bladder medication. A diary shows large voids and high fluid intake throughout the day. Address the volume pattern and contributing causes rather than assuming all frequency reflects reduced storage capacity.
Common pitfall: Counting toilet visits alone cannot distinguish polyuria from small-volume frequency. An incomplete diary or substantial unrecorded leakage also limits the conclusions that can be drawn.
50.When does urodynamics add value in female LUTS?
Urodynamics is most useful when resolving diagnostic uncertainty could change treatment, particularly before invasive intervention in a complex presentation. It is not routinely required before first-line treatment of uncomplicated overactive bladder or clearly demonstrated uncomplicated stress incontinence. Prior surgery, voiding difficulty, mixed or unclear symptoms and suspected neurological disease can increase its value. Ask what decision the test will change, and interpret findings alongside the patient's actual symptoms and treatment priorities.
Apply it
A woman with prior continence surgery has recurrent leakage and difficulty emptying. Because another operation could worsen obstruction, use selective urodynamic assessment to clarify the mechanism before choosing further invasive treatment and counseling about likely functional outcomes.
Common pitfall: Routine testing can add burden without changing uncomplicated initial care. Conversely, assuming all recurrent leakage has the original mechanism can miss postoperative obstruction or altered bladder function.
51.Why should prolapse and emptying be assessed together?
Pelvic organ prolapse can coexist with storage symptoms, stress leakage and impaired emptying. Initial examination should assess prolapse, pelvic floor function and relevant neurological findings rather than treating urgency in isolation. Postvoid residual measurement identifies incomplete emptying, although it does not establish its cause. The relationship between anatomy and function matters when choosing treatment and counseling about postoperative symptoms. A visible prolapse should not automatically be blamed for every urinary complaint.
Apply it
A woman with a vaginal bulge reports urgency and a slow stream. Assess the prolapse and measure residual urine before prescribing additional storage medication, then determine whether anatomy, detrusor function or another condition best explains the combined findings.
Common pitfall: Anatomical severity and symptom severity need not match. Treating urgency alone without assessing retention can overlook an important functional problem and complicate medication selection.
52.How do compliance and storage pressure guide renal protection in neurogenic bladder?
Compliance equals the change in bladder volume divided by the change in detrusor pressure during filling. Detrusor pressure is vesical minus abdominal pressure. An increase of 180 mL with a 30 cm H2O detrusor-pressure rise gives compliance of 6 mL/cm H2O, indicating poor accommodation. Low compliance and neurogenic detrusor overactivity can threaten the upper tracts. Treatment prioritizes safe low-pressure storage and reliable emptying, sometimes requiring intermittent catheterization.
Apply it
A relatively dry patient with spinal cord injury has poor compliance and new upper tract dilation. Reduce storage pressure and establish effective emptying rather than judging success by pad use.
Common pitfall: Dryness does not establish safety. Exclude abdominal-pressure artifacts and avoid increasing outlet resistance while storage remains unsafe.
53.How should autonomic dysreflexia during urodynamics be recognized and escalated?
In patients with spinal cord injury at or above T6, a systolic rise exceeding 20 mm Hg above baseline suggests autonomic dysreflexia; headache, flushing or sweating may occur. Consortium/PVA guidance recommends BP measurement at least every two minutes during urodynamics and more frequently during an episode. Stop filling and drain the bladder first. Persistent hypertension warrants a rapid-onset, short-duration antihypertensive, with treatment considered at adult systolic BP of 150 mm Hg or higher. Check recent PDE5-inhibitor use before nitrates. If drainage and medication fail, stop the procedure and sit the patient upright.
Apply it
A patient with a T4 injury develops headache and BP 168/94 from a baseline of 100/60 during filling. Drain the bladder, reassess BP every one to two minutes or more frequently, and escalate persistent hypertension after checking medication interactions.
Common pitfall: A relatively modest absolute BP can represent a dangerous rise from baseline. Nitrates can cause severe hypotension after recent PDE5-inhibitor use; continue monitoring after resolution for recurrent hypertension or treatment-related hypotension.
cpg_autonomic-dysreflexia-recommendations-final_single.pdf · EAU Guidelines on Neuro-urology
54.What long-term obligations follow augmentation cystoplasty?
Augmentation can increase capacity and lower storage pressure when less invasive treatment fails, but it creates lifelong management needs. Patients may require intermittent catheterization and attention to mucus, stones, infection and metabolic abnormalities. Perforation is a serious potential complication. Preoperative assessment must establish that the patient or caregiver can manage the reconstructed bladder and maintain follow-up. New abdominal pain or systemic illness after augmentation warrants assessment for structural complications rather than automatic attribution to uncomplicated UTI.
Apply it
A patient with an augmented bladder develops new abdominal pain, reduced catheter drainage and systemic illness. Seek urgent evaluation for perforation or another structural complication while assessing infection, instead of sending the patient home with treatment for presumed routine cystitis.
Common pitfall: A successful increase in bladder capacity does not remove surveillance needs. Reconstruction changes both the range of possible complications and the meaning of new symptoms.
Pediatric urology10%
55.When should persistent undescended testes be treated?
Spontaneous descent is unlikely after six months corrected for gestational age. Begin treatment planning then, aiming to complete orchiopexy by twelve months and no later than eighteen months under EAU guidance. Delay is associated with progressive germ-cell and Leydig-cell loss. Early positioning supports testicular preservation and later examination but does not abolish all future malignancy or fertility risks. Bilateral nonpalpable testes require additional attention to the possibility of an underlying endocrine or developmental disorder.
Apply it
An infant born prematurely still has a palpable inguinal testis at seven months corrected age. Arrange surgical management within the recommended infancy window rather than waiting for puberty or treating chronological age as interchangeable with corrected age.
Common pitfall: Waiting because descent sometimes occurs in early infancy overlooks the importance of the six-month boundary. Successful orchiopexy also does not make future risk counseling unnecessary.
56.How do examination findings distinguish retractile and nonpalpable testes?
A retractile testis can be brought into the scrotum and remains there temporarily without tension; regular examination is needed because secondary ascent can occur. A nonpalpable testis requires specialist localization. Routine ultrasound cannot reliably exclude an intra-abdominal testis, so a negative scan does not establish absence. Examination under anesthesia and operative assessment, often laparoscopy, determine the appropriate pathway. Selected developmental presentations may require additional endocrine or genetic evaluation.
Apply it
A testis that remains scrotal after gentle placement can be followed as retractile. A contralateral nonpalpable testis still needs specialist assessment even if ultrasound reports that no testis was seen.
Common pitfall: Neither a high position during one anxious examination nor a negative ultrasound establishes the diagnosis. Reassess a previously retractile testis if it no longer maintains a scrotal position.
57.When does childhood hydronephrosis require correction of ureteropelvic junction obstruction?
Hydronephrosis describes dilation and does not alone prove damaging obstruction. EAU [pediatric guidance](https://uroweb.org/guidelines/paediatric-urology/chapter/dilatation-of-the-upper-urinary-tract-puj-obstruction) integrates serial ultrasound, drainage assessment and split renal function. Recurrent flank pain or febrile UTI favors correction. Impaired split function below 40%, a fall exceeding 10 percentage points, poor drainage or worsening dilation strengthens the case for surgery. Interpret these findings together using comparable studies; pyeloplasty is the standard reconstructive operation.
Apply it
An infant with antenatal hydronephrosis develops worsening dilation and declining split renal function on comparable studies. Discuss pyeloplasty rather than continuing observation based solely on the absence of pain.
Common pitfall: A single drainage curve or pelvic diameter should not determine surgery in isolation. Conversely, a comfortable infant can still lose renal function.
ABU: Exam Content for Qualifying and In-service Examinations
58.How should spermatic-cord torsion be distinguished from appendage torsion?
Sudden severe pain, vomiting, abnormal testicular lie and an absent cremasteric reflex strongly suggest spermatic-cord torsion and warrant urgent exploration without delaying for imaging. Preserved Doppler flow can occur with early or partial torsion; manual detorsion does not replace surgery. Focal superior-pole tenderness or a blue dot suggests appendix testis torsion. Conservative analgesia and support are appropriate only after spermatic-cord torsion is confidently excluded; persistent pain or uncertainty can justify exploration.
Apply it
An adolescent with abrupt pain and a high horizontal testis needs immediate exploration. A child with securely diagnosed appendage torsion can receive supportive care and clear reassessment instructions.
Common pitfall: Pain relief after manipulation, visible arterial flow or a probable appendage diagnosis cannot independently exclude spermatic-cord torsion. Diagnostic delay can cost testicular viability.
59.Why can a child's neurogenic bladder require treatment before symptoms worsen?
A child with neurological bladder dysfunction may have impaired sensation and unsafe storage or emptying despite limited complaints. Management focuses on preserving the kidneys through risk assessment, pressure control and reliable drainage when indicated. Urodynamics and upper tract surveillance can reveal danger before obvious incontinence or infection develops. Decisions about medication and catheterization should follow the functional findings and the family's ability to implement care rather than waiting for symptomatic deterioration.
Apply it
A child with spina bifida has little urinary discomfort, but surveillance shows upper tract dilation and unsafe filling pressures. Initiate a coordinated pressure-lowering and emptying plan with caregiver teaching instead of waiting for pain or recurrent febrile infection.
Common pitfall: Absence of pain or severe wetting does not establish a safe neurogenic bladder. Sensory impairment makes objective renal and functional assessment especially important in follow-up.
60.What is the postnatal management sequence for posterior urethral valves?
EAU [pediatric guidance](https://uroweb.org/guidelines/paediatric-urology/chapter/congenital-lower-urinary-tract-obstruction) recommends initial bladder drainage for suspected neonatal posterior urethral valves. VCUG confirms the urethral diagnosis. Once the infant is medically stable and urethral access permits, perform endoscopic valve ablation. Maintain drainage if the urethra is too small; vesicostomy is an option when endoscopic treatment is not feasible or fails. Long-term care must assess renal function, bladder dysfunction, residual urine and polyuria because relief of the valves does not reverse established renal dysplasia.
Apply it
A newborn boy with a distended bladder, bilateral upper tract dilation and impaired renal function needs drainage and stabilization before definitive valve ablation, followed by continuing renal and bladder surveillance.
Common pitfall: Valve ablation does not establish lifelong renal safety. Persistent deterioration can reflect bladder dysfunction or intrinsic renal damage even after anatomical obstruction has been relieved.
ABU: Exam Content for Qualifying and In-service Examinations
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Give oncology the largest study allocation, emphasizing renal preservation, operational prostate surveillance, bladder restaging, muscle-invasive disease, systemic treatment and complete surgery for upper tract urothelial carcinoma.
- Rehearse emergency decisions: septic obstruction, traumatic urinary extravasation, urethral injury, penile fracture, autonomic dysreflexia and testicular torsion.
- Translate mechanisms into clinical interpretation: calculate BOOI and compliance, distinguish resistance from weak contraction, and connect drug targets, ureteral blood supply and acid-base abnormalities with management.
- Protect long-term function by addressing renal risk, recurrent stone mechanisms, fertility goals, pediatric obstruction and the metabolic and mechanical consequences of urinary reconstruction.
- Use the complete ABU outline to study areas beyond these selected concepts, especially transplantation, additional electrolyte emergencies, congenital disorders, pediatric tumors and broader operative complications.
A practical preparation plan
1. Map the full outline
Create a study schedule from the official eight-domain blueprint. Reserve approximately one quarter of domain-focused time for oncology and one fifth for core urology, while recognizing that stone and cancer complications also overlap with core content.
2. Build decision contrasts
For each concept, state the decisive distinction aloud: colonization versus infection, intraperitoneal versus extraperitoneal rupture, outlet obstruction versus detrusor weakness, or surveillance versus symptom-directed waiting.
3. Work the 20 questions independently
Choose one answer before reading the explanation. Record the clinical cue or calculation that determined your choice, then explain why each alternative fails in the particular case. Use results to locate learning gaps rather than estimate a passing probability.
4. Practise calculations and mechanisms
Recalculate sensitivity, specificity, BOOI and compliance with changed numbers. Connect alpha-blockers, 5-alpha-reductase inhibitors, beta-3 agonists, PDE5 inhibitors and testosterone to their physiological effects and important boundaries.
5. Recall, apply and broaden
Use the flashcards at spaced intervals, then apply each recalled principle to a different patient. Return to the official outline to add omitted topics and use primary clinical guidance to resolve management details.
6. Practise sustained pacing
Build toward the verified three-hour session length using mixed-domain questions. Review errors by mechanism, missed cue, calculation and treatment boundary; maintain effort throughout because field-test questions are not identified.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABU: Qualifying Examination (Part 1)
- ABU: Exam Content for Qualifying and In-service Examinations
- ABU: 2027 Information for Applicants and Candidates
- EAU Guidelines on Urological Infections: The Guideline
- EAU Guidelines on Urological Trauma
- EAU Guidelines on Urolithiasis: Guidelines
- CDC OneLab: Diagnostic Sensitivity and Specificity
- DailyMed: Mirabegron Extended-Release Tablets Prescribing Information
- EAU Male LUTS Guidelines: Diagnostic Evaluation
- EAU Male LUTS Guidelines: Disease Management
- EAU Urethral Stricture Guidelines: Disease Management in Males
- EAU Urolithiasis Guidelines: Metabolic Evaluation and Recurrence Prevention
- EAU Renal Cell Carcinoma Guidelines: Disease Management
- EAU Prostate Cancer Guidelines: Treatment
- EAU Non-muscle-invasive Bladder Cancer Guidelines: Diagnosis
- EAU Testicular Cancer Guidelines: Diagnostic Evaluation
- EAU Upper Tract Urothelial Carcinoma Guidelines: Disease Management
- EAU Sexual and Reproductive Health Guidelines: Erectile Dysfunction
- EAU Sexual and Reproductive Health Guidelines: Male Hypogonadism
- EAU Sexual and Reproductive Health Guidelines: Male Infertility
- EAU Female LUTS Guidelines: Diagnosis
- EAU Guidelines on Neuro-urology
- EAU Paediatric Urology Guidelines: Undescended Testes
- EAU Paediatric Urology Guidelines: Acute Scrotum
- cpg_autonomic-dysreflexia-recommendations-final_single.pdf
- DocumentsDownload.aspx
- download
- Dilatation of the Upper Urinary Tract Puj Obstruction - EAU Guidelines on Paediatric Urology - Uroweb
- Congenital Lower Urinary Tract Obstruction - EAU Guidelines on Paediatric Urology - Uroweb
- Disease Management - EAU Guidelines on MIBC - Uroweb
- Follow Up and Surveillance - EAU Guidelines on MIBC - Uroweb
- FDA approves durvalumab for muscle invasive bladder cancer | FDA
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.